Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density
Information source: Germans Trias i Pujol Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV
Intervention: Switch from tenofovir to abacavir (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Germans Trias i Pujol Hospital
Summary
Most of studies have not found any consistent drug-specific association with bone loss and
controversial data with respect the effect of protease inhibitors (PIs) have been published.
The more evident finding with respect to this issue is the more pronounced decrease of bone
mineral density (BMD) in patients during the first weeks of receiving a tenofovir
(TDF)-containing regimen, probably by the effect of TDF on phosphorus balance and vitamin D
metabolism.
Clinical Details
Official title: MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Bone mineral densityt-score change
Secondary outcome: viral loadCD4 T lymphocytes count Resistance test Lipid parameters (total, HDL-, LDL-cholesterol and triglyceride levels) Adverse Events
Detailed description:
The prevalence of osteoporosis in HIV-infected patients could be more than three times
greater compared with HIV-uninfected subjects, according to the results of a meta-analytical
review of cross-sectional published studies. The analysis includes data from 884
HIV-infected patients and 654 HIV-uninfected controls. Sixty-seven percent of HIV population
had reduced bone mineral density (BMD), of whom 15% had osteoporosis (OR of 6. 4 and 3. 7,
respectively, compared with HIV-uninfected controls).
In the same meta-analysis, when authors evaluated the role of antiretroviral therapy (ART)
on BMD, comparing 202 antiretroviral-naive with 824 ART-treated patients, patients on
treatment had a 2. 5-fold increased odds of prevalent reduced BMD and osteoporosis. And
finally, when 410 non-protease inhibitor (PI)-treated HIV patients were compared with 791
patients receiving a PI-containing regimen, those on PIs had increased odds of reduced BMD
and osteoporosis.
As well, other studies support data of an impaired BMD in HIV-infected patients after
starting antiretroviral therapy. These results let us confirm that HIV itself and
antiretroviral therapy contribute to decrease the BMD.
However, most of studies have not found any consistent drug-specific association with bone
loss and controversial data with respect the effect of PIs have been published. The more
evident finding with respect to this issue is the more pronounced decrease of BMD in
patients during the first weeks of receiving a tenofovir (TDF)-containing regimen, probably
by the effect of TDF on phosphorus balance and vitamin D metabolism.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Adult patients (=/+18 years old) having a diagnosis of HIV-1 infection.
2. Current HAART including tenofovir plus emtricitabine/lamivudine plus a PI, a NNRTI or
raltegravir started at least 12 months before.
3. T-score ≤-2 measured by DEXA (within the last 6 months).
4. Maintained undetectable plasma HIV-1 RNA (VL < 50 copies/mL) for at least 12 months.
5. Absence of suspected or documented resistance mutations in the RT associated to
abacavir.
6. Voluntary written informed consent.
Exclusion Criteria:
1. History of intolerance, toxicity or virological failure to abacavir.
2. HLA B*5701 positive.
3. Secondary osteoporosis/osteopenia (vitamin D or testosterone deficit, thyroid
disease, …)
4. Therapy with biphosphonates within the last 12 months.
Locations and Contacts
Hospital de la Santa Creu i Sant Pau, Barcelona 08041, Spain
Lluita contra la SIDA Foundation, Badalona, Barcelona 08916, Spain
Additional Information
Starting date: July 2010
Last updated: October 16, 2012
|